Thanks.
Yes i know zydus is better positioned in indian mkt but it never focused on US mkt because of issues i mentioned above.

My point was w.r.t US mkt biosimilar scenerio.
Although in 1st cut rosy stories it’s touted as a niche area which gives impression of monopolies and high margins and so on so on.

The fact is that pharma has changed a lot from 2007 when indian companies are plucking the low hanging fruits.

Now even biosimilars are converting into commodity at a fast pace although not same pace like generics.

But the situation is challenging and its difficult to have all the ingredients which were there in 2007.
Less competition and hence less erosion
Higher margins
Scale of economy * Higher margins for substantial time
Golden era of indian pharma.

In my view, we will have growth duration in coming years where biosimilars will play the same role as that of generics in 2007.
But how much margins * scale of economy * mkt share is a key area to watch/forecast.
Thanks

Thanks for sharing this perspective, most of the databases I have seen points to much higher price erosion in biosimilars (upto 70-80%) rather than only 50%. I also try to keep track of their US market shares at different points of time.

Pegfilgrastim (Fulphila) market share

Trastuzumab (Ogivri) market share

Insulin Glargine (Semglee) market share

Basically, they have struggled to get beyond 15% market share sustainably. For context, Indian generic cos generally get 30%+ market shares in small molecules, and thats when economies of scale start kicking in. Lets see if Biocon can improve this going ahead.

Sorry but this is incorrect, in India Zydus has a larger biosimilar portfolio than Biocon. Biocon has never focused on Indian market.

Disclosure: Not invested (no transactions in last-30 days)

Disc: not invested

A multiplier of 2 from 2.5 is set on Vstop since the valuation is slightly higher. ATR period 10 and 10.